Status:
WITHDRAWN
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Carcinoma
Colorectal Carcinoma
Eligibility:
All Genders
Brief Summary
This trial assesses current biomarker testing practices for common solid cancers in precision oncology in the community setting. Cancer biomarkers are used for diagnosing the disease, determining prog...
Detailed Description
PRIMARY OBJECTIVES: I. Determine capacity of pathology practices within National Cancer Institute (NCI) Community Oncology Research Program (NCORP) components/subcomponents for testing guideline-reco...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The study population is all onsite pathology practices within NCORP components and subcomponents that provide services to adult oncology groups.
- An onsite pathology practice is a laboratory (lab) that is financially administered and operated by an NCORP component or subcomponent. This excludes commercial reference laboratories, such as Quest and LabCorp. To describe biomarker testing practices across NCORP components/subcomponents, we will use the pathology practice as the unit of analysis. Participating components/subcomponents should meet \[element A\] AND \[at least one element of B OR C OR D\] AND element E.
- A) NCORP component/subcomponent provides services to adult oncology groups.
- B) A single onsite pathology lab (and its set of testing practices), may provide biomarker/pathology testing services to one or more components or subcomponents. Irrespective of the number of components/subcomponents that use this pathology lab, we will consider this as one pathology practice, and one unit of analysis.
- C) Several onsite pathology labs may provide services to one NCORP component or subcomponent, e.g. if the NCORP component or subcomponent represents a health system with several hospitals, and each hospital may have its own onsite pathology lab, with each pathology lab following its own set of testing practices. Therefore, each lab will represent one pathology practice and one unit of analysis.
- D) More than one onsite pathology lab may use a common set of testing practices and provide services to one or more NCORP components or subcomponents. Given common testing practices, we will consider these labs as one pathology practice, and one unit of analysis.
- E) The pathology practice has an informed individual who is willing to serve as a representative and gather information to complete the assessment items. This person typically is the pathology practice medical director, pathology practice administrative director and/or their designees.
Exclusion
Key Trial Info
Start Date :
January 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 29 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03804255
Start Date
January 8 2019
End Date
May 29 2020
Last Update
December 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Business Models in Healthcare
Chicago, Illinois, United States, 60625